(E)-6-chloro-3-(3-(2-chlorophenyl)acryloyl)-4-phenylquinolin-2(1H)-one | 1449373-00-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (E)-6-chloro-3-(3-(2-chlorophenyl)acryloyl)-4-phenylquinolin-2(1H)-one
• 英文别名: 6-chloro-3-[(E)-3-(2-chlorophenyl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one
• CAS: 1449373-00-5
• 化学式: C₂₄H₁₅Cl₂NO₂
• 分子量: 420.295
• InChiKey: CLLHXWPLNUTOQA-JLHYYAGUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-6-chloro-3-(3-(2-chlorophenyl)acryloyl)-4-phenylquinolin-2(1H)-one 在 肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 0.66h， 生成 4-(3-(6-chloro-2-oxo-4-phenyl-1,2-dihydroquinolin-3-yl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)-4-oxobutanoic acid
  参考文献：
  名称：

  Structure–Activity Relationships and Pharmacophore Model of a Noncompetitive Pyrazoline Containing Class of GluN2C/GluN2D Selective Antagonists

  摘要：

  Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC50 of 0.17-0.22 mu M at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.

  DOI：

  10.1021/jm400652r
• 作为产物：
  描述：

  2-氨基-5-氯二苯甲酮 在 potassium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.88h， 生成 (E)-6-chloro-3-(3-(2-chlorophenyl)acryloyl)-4-phenylquinolin-2(1H)-one
  参考文献：
  名称：

  Structure–Activity Relationships and Pharmacophore Model of a Noncompetitive Pyrazoline Containing Class of GluN2C/GluN2D Selective Antagonists

  摘要：

  Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC50 of 0.17-0.22 mu M at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.

  DOI：

  10.1021/jm400652r

文献信息

• An Expedient Approach for the Synthesis of Bioactive Pyrazole, Isoxazole and Benzodiazepine-Substituted Quinolin-2(1<i>H</i>)-one Derivatives
  作者：Mathan Sankaran、Chokkalingam Uvarani、Kumarasamy Chandraprakash、Mani Umamaheswari、Palathurai Subramaniam Mohan

  DOI：10.1002/jhet.2192

  日期：2015.7

  These approaches lead to the synthesis of hitherto unknown compounds with a varied substitution pattern by both conventional and microwave‐assisted method. A good number of analogues were evaluated for their in vitro cytotoxicity against human cervical and colon cancer cell lines by MTT protocol. Almost all the selected compounds showed remarkable cytotoxic activities. Among them, compound 4g and 4i

  从易于获得的起始前体开始，以高收率合成了一系列功能化的吡唑，异恶唑和苯并二氮杂取代的喹诺酮衍生物。这些方法可以通过常规方法和微波辅助方法合成迄今未知的具有不同取代模式的化合物。通过MTT方案评估了大量类似物对人宫颈癌和结肠癌细胞系的体外细胞毒性。几乎所有选择的化合物都显示出显着的细胞毒性活性。其中，化合物4g和4i成为最有前途的支架。这些支架将用于进一步的分子水平研究。
• Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20050165053A1

  公开（公告）日：2005-07-28

  The present invention is directed to substituted 4-Aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogs thereof, represented by the general Formula I: wherein Ar 1 , Ar 2 , R 1 -R 6 and R 12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及替代的4-芳基-3-(3-芳基-1-氧代-2-丙烯基)-2(1H)-喹啉酮及其类似物，由通式I所表示，其中Ar1，Ar2，R1-R6和R12在此被定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。本发明的化合物可用于在许多临床情况下诱导细胞死亡，其中存在异常细胞的不受控制的生长和扩散。
• Heteroaryl inhibitors of PAD4
  申请人：PADLOCK THERAPEUTICS, INC.

  公开号：US11026937B2

  公开（公告）日：2021-06-08

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了可用作 PAD4 抑制剂的化合物、其组合物以及治疗 PAD4 相关疾病的方法。
• HETEROARYL INHIBITORS OF PAD4
  申请人：PADLOCK THERAPEUTICS, INC.

  公开号：US20210299115A1

  公开（公告）日：2021-09-30

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
• Structure–Activity Relationships and Pharmacophore Model of a Noncompetitive Pyrazoline Containing Class of GluN2C/GluN2D Selective Antagonists
  作者：Timothy M. Acker、Alpa Khatri、Katie M. Vance、Cathryn Slabber、John Bacsa、James P. Snyder、Stephen F. Traynelis、Dennis C. Liotta

  DOI：10.1021/jm400652r

  日期：2013.8.22

  Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC50 of 0.17-0.22 mu M at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.